MDS Congress Scientific Program Committee member, Hélio AG Teive (Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil) kindly talked to us about spinocerebellar ataxia and its geographical diversity.
1. How does spinocerebellar ataxia differ from other ataxias? (0:05)
2. In what regions is spinocerebellar ataxia found? (0:26)
3. What is the reason for this geographical diversity? (1:09)
4. What are the major challenges in clinically differentiating the different genotypes and phenotypes in spinocerebellar ataxia? (1:33)
5. What have been the most important advances in the diagnosis and management of spinocerebellar ataxia? (2:03)
Speaker disclosure: Hélio AG Teive has nothing relevant to disclose in relation to this video interview.
Filmed at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Nice, France, September 2019.
Share this Video
Related Videos In Movement Disorders
World Congress on Controversies in Neurology (CONy): Presidential highlights, Amos D. Korczyn
The 17th World Congress on Controversies in Neurology (CONy) took place March 23-25 2023 in Dubrovnik, Croatia. Prof. Amos D. Korczyn, CONy President (University of Tel-Aviv, Tel-Aviv, Israel) joined touchNEUROLOGY to discuss the main aims and focus of the recent CONy meeting, the unique debate presentation style, and the most exciting debates, topics and highlights […]
Francisco Cardoso: International Parkinson and Movement Disorder Society (MDS) – President update
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals, who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. touchNEUROLOGY caught up with the MDS President, Prof. Francisco Cardoso, to discuss the upcoming […]
Donald Gilbert, AAN 2022: Ecopipam investigated for the treatment of children and adolescents with Tourette’s syndrome – Phase 2b results
Ecopipam is an investigational first-in-class drug being evaluated for the treatment of children and adolescents with Tourette’s syndrome. Prof. Donald Gilbert (Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA) discusses the randomised, double-blind, placebo-controlled phase 2b study investigating ecopipam. The abstract entitled ‘Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!